D.C.-based Danaher Corp. is acquiring Boston-based General Electric Co.’s biopharma business for $21.4 billion in an all-cash deal announced Monday.
GE Biopharma, part of GE Life Sciences, supports research, development and manufacturing of biopharmaceutical drugs. The unit, consisting of instruments, technologies and consumables, is expected to generate roughly $3.2 billion in 2019 revenue, according to a release.
The transaction’s net price comes to about $20 billion with tax benefits, 17-times…
